Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | CXCR4 | P61073 | 6/20 | 0.38 |
| ▸ | BCHE | P06276 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | MC4R | P32245 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL334953 | 0.96 | ALDH1A1 (0.39) | ACHEALDH1A1CHRM2TAAR1BCHE | |
| SCHEMBL1132754 | 0.90 | TAAR1 (0.41) | ACHEALDH1A1TAAR1CA1CA2 | |
| SCHEMBL334999 | 0.90 | TAAR1 (0.41) | ACHEALDH1A1TAAR1CA1CA2 | |
| SCHEMBL10245606 | 0.83 | CHRM2 (0.43) | ACHEALDH1A1CHRM2BCHE | |
| SCHEMBL10245022 | 0.83 | CA1 (0.44) | ACHEALDH1A1CA1CA2MC4R | |
| SCHEMBL11886646 | 0.83 | CA1 (0.44) | ACHEALDH1A1CA1CA2MC4R | |
| SCHEMBL10243168 | 0.82 | CHRM2 (0.48) | ACHECHRM2BCHE | |
| SCHEMBL10244526 | 0.82 | SLC6A4 (0.40) | ACHEALDH1A1CHRM2BCHECA1 | |
| SCHEMBL334443 | 0.81 | BCHE (0.47) | ACHECHRM2BCHE | |
| SCHEMBL334589 | 0.81 | MC4R (0.38) | ACHEALDH1A1BCHECA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299035-B2 | 10a-azalide compound having 4-membered ring structure | TAISHO PHARMACEUTUCAL CO., LTD. (JP) | 2012-10-30 | — | — | US | disclosed |
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20110152239-A1 | 10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-06-23 | — | — | US | disclosed |
| EP-2287173-A1 | 10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE | Taisho Pharmaceutical Co., Ltd. (JP) | 2011-02-23 | — | — | EP | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1985620-A1 | 10a-AZALIDE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2008-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152239-A1 | 10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE | ELOVL3, ELOVL5, SCD5 | ACHE 1195/4885ALDH1A1 3050/4885CHRM2 3997/4885 |
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | ACHE 1324/4885ALDH1A1 1939/4885CHRM2 3989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.